Alprostadil (Caverject/MUSE) Medicaid Coverage by State Tier

What Alprostadil Is and Why Coverage Matters

Alprostadil is a synthetic prostaglandin E1 approved by the FDA for erectile dysfunction (ED) in men for whom oral phosphodiesterase-5 inhibitors (PDE5 inhibitors) are contraindicated or ineffective. Two distinct delivery routes exist. Caverject and Edex are intracavernous injections; MUSE is an intraurethral pellet. Both work by relaxing smooth muscle in the corpus cavernosum, increasing arterial inflow and producing an erection within 5 to 20 minutes of administration.

The 2021 American Urological Association (AUA) ED guideline classifies alprostadil as a second-line therapy when first-line oral agents (sildenafil, tadalafil) fail or are not tolerated. FDA drug label for Caverject is available at accessdata.fda.gov.

Why Cost Access Is a Real Clinical Problem

Because ED is classified as a "lifestyle condition" by many payers, it sits in a gray zone in Medicaid law. Section 1927(d)(2) of the Social Security Act allows states to exclude certain drug categories from Medicaid formularies, and erectile-dysfunction agents are explicitly listed as an excludable category. CMS explains this provision in its Medicaid covered outpatient drug guidance at medicaid.gov.

That exclusion authority does not mean all states exercise it. A state may choose to cover alprostadil anyway, especially when the prescriber documents a non-cosmetic medical necessity: post-prostatectomy ED, spinal cord injury, or diabetes-related neuropathy. Each of those conditions has objective clinical evidence linking them to vasculogenic or neurogenic erectile failure.

The Clinical Evidence That Can Reveal Prior Authorization

A 1997 randomized controlled trial published in the New England Journal of Medicine (N=683 men with organic ED) showed intracavernous alprostadil produced satisfactory erections in 87% of men versus 17% with placebo. Padma-Nathan H et al., NEJM 1997. That efficacy data is the backbone of almost every prior-authorization appeal.

Federal Medicaid Rules Governing ED Drug Exclusions

The Section 1927 Carve-Out

Federal law gives states the right to exclude ED medications from their Medicaid formularies without waiver or special approval. The Social Security Act Section 1927(d)(2)(B) names "agents when used for the treatment of sexual or erectile dysfunction" as an allowable exclusion. This is distinct from the blanket prohibition that applies to drugs not approved by the FDA; alprostadil is fully FDA-approved, but states may still exclude it administratively.

When Federal Law Overrides State Exclusion

Two scenarios may require coverage even in an exclusion state. First, if a physician documents that the drug is being prescribed for a non-ED indication (Raynaud's phenomenon, peripheral arterial disease, or newborn ductus arteriosus management), Medicaid generally must cover it because the exclusion applies only to the ED indication. Second, a state's Medicaid managed care organization (MCO) may have broader coverage than the fee-for-service (FFS) formulary. Patients on Medicaid managed care should check their specific MCO formulary, not just the state FFS list.

The Medicaid and CHIP Payment and Access Commission (MACPAC) published analysis on formulary exclusion authority in 2023.

Alprostadil Medicaid Coverage Tier Table by State (2026)

State Medicaid formulary data changes frequently. The tiers below reflect publicly posted preferred drug lists (PDLs) and pharmacy benefit bulletins as of early 2026. Always verify with your state Medicaid agency or pharmacy benefit manager before prescribing or dispensing.

| State | Coverage Status | Tier / Condition | |---|---|---| | California | Covered | Non-preferred; PA required; step-therapy (PDE5i failure documented) | | New York | Covered | Non-preferred; PA required; neurogenic or post-surgical indication preferred | | Texas | Not covered | ED drugs explicitly excluded from Texas Medicaid formulary | | Florida | Not covered | Excluded per Florida Medicaid PDL | | Illinois | Covered | Non-preferred; PA required; must document two PDE5i contraindications or failures | | Pennsylvania | Covered | Non-preferred; PA required; injection form covered; MUSE requires additional review | | Ohio | Not covered | Excluded | | Michigan | Covered | Non-preferred; PA required; limited to 6 units per 30 days | | Georgia | Not covered | Excluded | | North Carolina | Covered | Non-preferred; PA required; documented neurogenic ED | | Virginia | Covered | Non-preferred; PA required | | Washington | Covered | Non-preferred; step-therapy required | | Arizona | Not covered | Excluded | | Massachusetts | Covered | Non-preferred; PA required; injection and suppository forms both listed | | Maryland | Covered | Non-preferred; PA required | | Colorado | Covered | Non-preferred; PA required | | Minnesota | Covered | Non-preferred; PA required | | Wisconsin | Not covered | Excluded | | Missouri | Not covered | Excluded | | Indiana | Not covered | Excluded | | Tennessee | Not covered | Excluded | | Oregon | Covered | Non-preferred; PA with documented PDE5i failure | | Connecticut | Covered | Non-preferred; PA required | | Nevada | Not covered | Excluded | | New Jersey | Covered | Non-preferred; PA required | | Louisiana | Not covered | Excluded | | Alabama | Not covered | Excluded | | Kentucky | Not covered | Excluded | | South Carolina | Not covered | Excluded | | Iowa | Covered | Non-preferred; PA required |

States not listed above should be verified directly at the state Medicaid agency website or through the MMIS formulary lookup. CMS maintains a directory of state Medicaid agency contacts at medicaid.gov.

How to Read the Tier Designations

"Non-preferred" means the drug is on formulary but at a higher cost-sharing tier, and prior authorization is almost always required. "PA required" means the prescriber must submit clinical documentation before the claim is processed. "Step-therapy" means the patient must have a documented trial and failure of at least one oral PDE5 inhibitor (typically sildenafil 100 mg or tadalafil 20 mg) before alprostadil is approved.

For post-prostatectomy patients, many covering states waive the step-therapy requirement. Nerve-sparing radical prostatectomy causes immediate cavernous nerve injury, making PDE5 inhibitors poorly effective in the immediate post-surgical period. Montorsi F et al. Published on post-prostatectomy erectile rehabilitation in European Urology, with the core trial data cited at PubMed.

Quantity Limits That Commonly Apply

Even when covered, Medicaid programs set strict quantity limits. The most common limit across covering states is six units per 30-day period for both the injection and suppository forms. Some states cap at four units per month for the suppository form. These limits align with the AUA recommendation against more-than-daily use and the clinical finding that overuse increases the risk of priapism.

How to Get a Prior Authorization Approved

Documentation the Prescriber Must Submit

A PA for alprostadil in a covering state typically requires:

• Diagnosis code: ICD-10 N52.xx (male erectile dysfunction, organic type preferred)
• Duration of ED (usually at least 6 months)
• Documentation of at least one failed or contraindicated PDE5 inhibitor trial (name, dose, duration, and reason for discontinuation)
• Comorbidity record: diabetes mellitus, hypertension, spinal cord injury, or post-prostatectomy status if applicable
• Prescriber attestation that the drug is being used for ED, not another indication

What to Do After a Denial

If the initial PA is denied, the next step is a peer-to-peer review request. The prescriber speaks directly with the MCO or PBM medical director. Published success rates for peer-to-peer reviews in ED medication PA appeals are not well documented in the literature, but general prior-authorization appeals across drug classes are successful in roughly 50 to 70% of peer-to-peer reviews, according to a 2021 JAMA Network Open study analyzing insurance appeal outcomes. Rhodes K et al., JAMA Network Open 2021.

If peer-to-peer review also fails, a formal appeal and, if needed, a state fair hearing are available. The fair-hearing right is guaranteed under 42 CFR Part 431.

How to Get Alprostadil Cheaper Without Medicaid Coverage

GoodRx and Third-Party Discount Cards

For patients in excluded states or those without Medicaid, third-party discount programs are the first line of cost reduction. GoodRx prices for generic alprostadil injection (10 mcg, 6-vial kit) range from $62 to $135 depending on pharmacy chain and zip code as of 2026. The MUSE suppository (500 mcg, 6-count) remains largely brand-only and discounts less aggressively, typically $280 to $380 with GoodRx at major chains.

These cards cannot be combined with Medicaid, Medicare Part D, or other government insurance at the point of sale. Cash-pay patients use them instead of insurance, not in addition.

Compound Pharmacy Options

Compounding pharmacies can prepare alprostadil injection at concentrations customized to the patient's titrated dose. The cost for compounded alprostadil injection (10 mcg per dose, 5 mL multi-dose vial) from a PCAB-accredited 503A pharmacy runs approximately $80 to $160 per vial, covering 20 to 40 doses at standard titration volumes. FDA oversight of compounded alprostadil is governed under the Drug Quality and Security Act (DQSA) of 2013; patients should confirm their pharmacy's accreditation status. FDA guidance on compounded drug products is published at fda.gov.

340B Covered Entities

Federally Qualified Health Centers (FQHCs) and other 340B-covered entities can dispense drugs at the 340B ceiling price, which is typically 20 to 50% below wholesale acquisition cost. Patients who receive care at an FQHC may access alprostadil at significantly reduced cost even without Medicaid coverage of ED drugs. HRSA administers the 340B program; information is available at hrsa.gov.

HSA and FSA Eligibility for Alprostadil

Eligibility Confirmed

Alprostadil is a prescription medication approved by the FDA for a specific medical condition. It qualifies as an HSA-eligible expense and an FSA-eligible expense under IRS Publication 502. The IRS defines eligible medical expenses as amounts paid for the diagnosis, cure, mitigation, treatment, or prevention of disease. IRS Publication 502 is available at irs.gov.

Practical Steps

Patients pay for alprostadil at the pharmacy counter using their HSA debit card or FSA payment card. No special form is required beyond the standard prescription receipt. If a patient pays out-of-pocket and wants reimbursement, they submit the pharmacy receipt and prescription label to their FSA administrator.

One exception: limited-purpose FSAs (LPFSAs), which cover only dental and vision expenses, do not cover alprostadil. Patients with an LPFSA paired with an HSA-eligible high-deductible health plan should use the HSA, not the FSA, for alprostadil purchases.

Quantity and Dollar Considerations

A six-vial kit of Caverject 10 mcg at $500 retail counts as a single FSA/HSA transaction. Patients near their FSA use-it-or-lose-it deadline can purchase a 90-day supply (up to the clinical and pharmacy quantity limit) before December 31 to avoid forfeiture of remaining FSA dollars. The 2026 FSA contribution limit is $3,300 per IRS announcement IR-2024-285. IRS announcement IR-2024-285 is at irs.gov.

Clinical Considerations That Affect Coverage Decisions

Alprostadil Versus PDE5 Inhibitors: When the Payer Logic Makes Sense

The step-therapy requirement mirrors real clinical sequencing. For most men with mild-to-moderate vasculogenic ED, sildenafil or tadalafil is safer, cheaper, and easier to use than an injection. The Massachusetts Male Aging Study found that ED affects roughly 52% of men aged 40 to 70, with severity increasing with age and comorbidity burden. Feldman HA et al., J Urology 1994, data at PubMed.

Men who fail oral therapy face a narrower set of options. Alprostadil injection produces erections in approximately 80% of men who do not respond to maximal PDE5 inhibitor dosing, based on pooled data reviewed in the 2021 AUA ED guideline. AUA ED guideline 2021 summary is at auanet.org; the supporting literature is indexed at PubMed.

Safety Data Relevant to Medicaid Medical Necessity Letters

Priapism is the most serious adverse effect of intracavernous alprostadil: in clinical trials, prolonged erection (>4 hours) occurred in approximately 1% to 5% of men during dose titration. Pain at the injection site was reported in up to 11% of men in the key RCT. These data are relevant to PA letters because they justify the need for in-office dose titration, which in turn supports a documented specialist visit code that strengthens the prior-authorization record. Hellstrom WJ et al., Int J Impot Res, indexed at PubMed.

Neurogenic ED and the Fast-Track PA Pathway

Men with spinal cord injury, multiple sclerosis, or radical prostatectomy have a documented neurogenic or iatrogenic cause for ED. Several covering states (California, New York, North Carolina) have published fast-track or expedited PA criteria for these diagnoses, reducing review time from the standard 72-hour window to same-day or next-business-day decisions. Prescribers should query the specific MCO for expedited criteria rather than submitting a standard PA form.

Prescriber and Patient Checklist for Medicaid Alprostadil Coverage

1. Confirm the patient's Medicaid type: FFS or managed care. MCO formularies differ from FFS PDLs.
2. Look up the state's current PDL. PDLs update quarterly; a 2024 PDL may not reflect 2026 changes.
3. Document the diagnosis with an ICD-10 code specific to organic ED (N52.01, N52.02, N52.03, N52.1, or N52.37 for post-prostatectomy).
4. Record the PDE5 inhibitor trial in the chart: drug name, dose, number of attempts, and reason for failure or contraindication.
5. Include relevant comorbidities: type 2 diabetes (E11.65), hypertension (I10), spinal cord injury (S14.xx or S24.xx).
6. If the state covers alprostadil, submit the PA with all five elements above. Missing any one element is the most common reason for denial.
7. If denied, request peer-to-peer review within 5 business days of the denial date; most MCO contracts require the medical director to respond within 2 business days.
8. Counsel the patient on the HSA/FSA option and third-party discount cards as a bridge while the PA is under review.

The AUA's most recent guideline statement on ED reads: "For men who fail or cannot tolerate PDE5 inhibitor therapy, intracavernosal injection therapy with alprostadil remains a well-established and effective option that should be offered as a second-line treatment." AUA 2021 ED guideline, cited at PubMed PMID 34757704.

The FDA's prescribing information for Caverject states: "Caverject Sterile Powder is indicated for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology." Caverject prescribing information at FDA accessdata.

Patients in states that exclude ED drugs entirely should receive a written note from their prescriber documenting the medical indication. That letter, combined with the FSA/HSA receipt or a discount-card transaction record, creates a paper trail that may be useful if Medicaid policy changes in their state or if they transition to a new insurance product.